3-METHYL-2- ( (2S) -2- (4- (3-METHYL-L, 2, 4-0XADIAZ0L-5-YL) PHENYL) MORPHOLINO) -6- (PYRIMIDIN-4-YL) PYRIMIDIN-4 (3H) -ONE AS TAU PROTEIN KINASE INHIBITOR
A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g.
-
Page/Page column 10; 11
(2009/04/25)
6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE
A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g.
-
Page/Page column 10-11
(2009/04/25)
INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF
The present invention relates to a production method of an optically active morpholine compound represented by the formula 10, which includes the following steps: wherein each symbol is as defined in the specification. The present invention also relates t
-
Page/Page column 90-91
(2008/06/13)
REMOVAL OF N-BENZYL- AND N-BENZYLOXYMETHYL SUBSTITUENTS FROM SUBSTITUTED URACILS WITH BORON TRIBROMIDE
N1,N3-Dibenzyl uracil derivatives have been successfull deblocked by using boron tribromide in refluxing xylene.Also, N1,N3-dibenzyloxy methyl uracil derivatives can be easily converted to uracils by treatment with boron tribromide in benzene in the cold and subsequent boiling of the intermediate with water.
Kundu, Nitya G.,Hertzberg, Robert P.,Hannon, Stephen J.
p. 1109 - 1112
(2007/10/02)
More Articles about upstream products of 1747-53-1